Aquinnah’s unique scientific approach has been recognized nationally by receiving nine highly competitive peer-reviewed grants, two from the ALS Association, four from the National Institute of Health, two from the Alzheimer’s Association and Rainwater Foundation Tau Consortium and one from the Massachusetts Life Science Center.
Aquinnah's therapeutic drug development compounds adhere to rigorous standards, demonstrating potency, oral (pill) bioavailability, brain uptake and demonstrated efficacy in animal models of neurodegenerative diseases, where our compounds exhibit robust and beneficial effects. Patient clinical trials will be forthcoming, following successful completion of studies required by the FDA.
These outcomes serve as compelling validation for Aquinnah's drug discovery pipeline. Our deep understanding of the molecular processes driving neurodegenerative diseases, coupled with our globally acclaimed chemistry, biology, and development team, which has empowered Aquinnah to progress towards the clinic with first in class compounds directed against these devastating diseases.
Both Dr. Larsen and Dr. Wolozin are very optimistic about the future of our pipeline to imminently demonstrate therapeutic utility in our lead programs for ALS and Alzheimer’s diseases.
